Lyrfigtu (lirafugratinib)

Lyrfigtu (lirafugratinib) is filed as FGFR2 inhibitor. The sections below restate public label fields stored for this profile.

Class
FGFR2 inhibitor
Generic name
lirafugratinib
Generic available
No

Approved uses

To treat adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

Common questions

What is Lyrfigtu approved to treat?

According to its FDA label, Lyrfigtu (lirafugratinib) is approved for: To treat adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Lyrfigtu?

Lyrfigtu (lirafugratinib) belongs to the FGFR2 inhibitor class of medications.

Is there a generic version of Lyrfigtu?

Not yet. As of the most recent FDA data we ingest, no A-rated generic equivalent is listed for Lyrfigtu. Availability changes as patents expire.

Does Lyrfigtu have a Boxed Warning?

Our ingest of the FDA label for Lyrfigtu (lirafugratinib) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

Is Lyrfigtu currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Lyrfigtu (lirafugratinib) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Lyrfigtu approved by the FDA?

The FDA record lists the approval date for Lyrfigtu (lirafugratinib) as 2026-09-23.

Loading full data from Know Your Drugs Institute…